- Report
- February 2024
- 175 Pages
Global
From €4797EUR$5,000USD£4,132GBP
- Report
- August 2023
- 110 Pages
Global
From €4701EUR$4,900USD£4,049GBP
- Clinical Trials
- April 2024
- 60 Pages
Global
From €1919EUR$2,000USD£1,653GBP
- Clinical Trials
- April 2024
- 60 Pages
Global
From €1439EUR$1,500USD£1,240GBP
- Clinical Trials
- February 2024
- 60 Pages
Global
From €1199EUR$1,250USD£1,033GBP
- Clinical Trials
- January 2024
- 60 Pages
Global
From €1439EUR$1,500USD£1,240GBP
- Report
- June 2020
- 112 Pages
Global
From €4558EUR$4,750USD£3,925GBP
- Report
- October 2023
- 230 Pages
Global
From €3425EUR$3,570USD£2,950GBP
- Book
- June 2021
- 976 Pages
- Book
- January 2020
- 112 Pages
- Book
- May 2018
- 872 Pages
- Book
- August 2013
- 462 Pages
Global
- Book
- April 2010
- 486 Pages
Global
- Book
- May 2024
United States
- Book
- May 2023
North America
The psychotropic treatment market is a subset of the mental health industry that focuses on the use of psychotropic medications to treat mental health disorders. These medications are used to treat a wide range of mental health conditions, including depression, anxiety, bipolar disorder, schizophrenia, and attention-deficit/hyperactivity disorder (ADHD). The psychotropic treatment market is composed of pharmaceutical companies, medical device manufacturers, and healthcare providers.
Pharmaceutical companies develop and manufacture psychotropic medications, which are then prescribed by healthcare providers. Medical device manufacturers produce devices such as transdermal patches and inhalers that are used to deliver psychotropic medications. Healthcare providers, such as psychiatrists, psychologists, and primary care physicians, are responsible for prescribing psychotropic medications to patients.
Some companies in the psychotropic treatment market include Pfizer, Johnson & Johnson, Eli Lilly, GlaxoSmithKline, Novartis, and Merck. Show Less Read more